Development and characterization of a doxorubicin-resistant triple-negative breast cancer spheroid model for drug screening purposes

µg/µg protein) over a 96-h treatment period. A chemotherapeutic responsive MDA-MB 231 TNBC spheroid model was successfully developed and characterized. The spheroid model demonstrated sensitivity towards a clinical dose of cisplatin, whilst displaying resistance to a clinical dose of doxorubicin, based on the viability parameters.